A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.

Summary: Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that mostly affects kids and young adults. It is caused by a mutant protein in the body. Normal drugs that target this protein are too toxic. So, doctors tried a new idea: a vaccine that trains the body's immune system to attack the cancer. In a small study of 16 patients, doctors gave this new vaccine along with other immune-boosting drugs. The results were very promising! Most patients who finished the first round of shots had their immune cells learn to fight the cancer. The cancer stopped growing in 9 out of 12 patients, and tumors actually shrank in 3 of them. Some patients did have severe side effects, but the study shows that vaccines could be a great new way to treat hard-to-cure cancers.